Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients.

Next Previous
Search
Trial Profile

A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Mar 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pramipexole (Primary) ; Ropinirole
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 14 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
  • 09 Dec 2008 Status changed from recruiting to active, no longer recruiting, as reported on ClinicalTrials.gov.
  • 11 Dec 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top